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Objective: This study aimed to evaluate whether circulating levels and/or visceral adipose tissue (VAT)
expression of recently described adipokines associate with histopathological severity of nonalcoholic fatty
liver disease (NAFLD), independent of obesity and insulin resistance.
Methods: Serum levels of adiponectin, omentin, chemerin, monocyte chemoattractant protein-1, and
secreted frizzled-related protein 4 were measured using enzyme-linked immunosorbent assay in 81
patients with obesity and NAFLD and 18 lean control subjects. Expression in VAT was measured using
real-time PCR and histopathological grading was scored using the NAFLD activity score (NAS).
Results: When NAFLD patients were subdivided into groups with simple steatosis, borderline nonalcoholic
steatohepatitis (NASH), and NASH, adiponectin serum levels and omentin expression were lower in NASH
versus simple steatosis patients. Serum adiponectin was generally lower with higher histopathological grad-
ing. Chemerin VAT expression was negatively associated with NAS (r 5 20.331, P 5 0.022) and steatosis
score (r 5 20.335, P 5 0.020), independent of age, BMI, and HOMA-IR. In addition, adjusting for chemerin
VAT expression in a multivariate model explained part of the association between NAS and HOMA-IR.
Conclusions: These findings suggest that lower VAT expression of chemerin in patients with obesity may
be involved in the pathophysiology of hepatic steatosis, potentially by modulating the link between insulin
resistance and NAFLD.
Obesity (2016) 24, 2544-2552. doi:10.1002/oby.21674
Introduction
The growing epidemic of obesity has led to a simultaneously increased
prevalence of nonalcoholic fatty liver disease (NAFLD), often referred
to as the hepatic manifestation of metabolic comorbidity (1). NAFLD
is a chronic liver disease that encompasses a broad histopathological
spectrum ranging from simple steatosis (SS) to nonalcoholic steatohe-
patitis (NASH) and is associated with a higher risk of developing cir-
rhosis and hepatocellular carcinoma (2). To better address this growing
health problem, more insight in the pathophysiology is needed.
Recent data have indicated that adipose tissue-derived secretory fac-
tors (adipokines) could play a role in the development of NAFLD and
influence disease progression (3). Many adipokines have already been
described, and several studies have suggested that they play a role in
whole-body energy homeostasis and/or inflammatory responses (4),
thus possibly influencing metabolic abnormalities in peripheral tissues
in persons with obesity. Elevated chemerin levels have been described
frequently in patients with metabolic syndrome and have been associ-
ated with body mass index (BMI), serum glucose, triglycerides (TG),
high-density lipoprotein (HDL) cholesterol levels, and blood pressure
(5). Chemerin is also known to be involved in inflammation by induc-
ing chemotaxis and to induce insulin resistance in skeletal muscle cells
(6,7). In contrast, adiponectin and omentin have been found to display
anti-inflammatory, insulin-sensitizing, and cardioprotective properties
(8,9). Monocyte chemoattractant protein-1 (MCP-1), an adipokine of
which higher levels are described in obesity and insulin resistance, has
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also been suggested to play a role in hepatic inflammatory and fibrogenic
processes (10,11). Finally, secreted frizzled-related protein 4 (SFRP4), a
modulator of the Wnt signaling pathway, has also been described as an
adipokine (12), and several Wnt pathway components are associated
with lipid and glucose metabolism as well as inflammation (13). Overall,
hepatic insulin resistance, inflammation, and modulation of the activity
of the Wnt signaling pathway have been reported repeatedly in NAFLD
patients, suggesting a common link that potentially contributes to
obesity-related NASH (1,14,15). In this study, we assessed serum levels
as well as visceral adipose tissue (VAT) expression of chemerin, adipo-
nectin, omentin, MCP-1, and SFRP4 in patients with biopsy-proven
NAFLD and lean controls. We hypothesized that a disturbed signature of
these adipokines may contribute to the progression of SS to an inflamma-
tory and insulin-resistant NASH status. Therefore, we aimed to evaluate
whether these adipokines associate with histopathological disease sever-
ity, independent of known insulin resistance in obesity.
Methods
Study design and subjects
Ninety Caucasian patients with obesity (57 men and 33 women; mean
BMI 41 kg/m2), aged between 20 and 68, were recruited from the
NASH and Hepobster cohort for evaluation in this study. All patients
were scheduled for gastric banding or gastric bypass surgery and met
the criteria for bariatric surgery of the International Federation for the
Surgery of Obesity: BMI 40 kg/m2 or BMI 35 kg/m2 in conjunc-
tion with obesity-induced comorbid conditions. Twenty men with obe-
sity had type 2 diabetes. Liver and VAT biopsies were obtained during
surgery and patients with other causes of liver disease, e.g., hepatitis B
or C, viral or autoimmune hepatitis, Wilson disease or any drug-
induced liver disease, or evidence of excessive alcohol consumption
(20 g per day), were excluded. Additional exclusion criteria were
primary hypogonadism, abnormal thyroid function, malignancies or
carcinoma, serum total cholesterol >300 mg/dL, and/or TG >450 mg/
dL. None of the subjects used steroids, insulin, or thiazolidinediones,
and oral glucose-lowering medication was discontinued before surgery.
For comparison, 18 Caucasian control men (mean BMI 24 kg/m2;
mean age 446 12 years) from the Hepobster cohort were recruited.
These men underwent elective abdominal surgery for adhesiolysis, her-
nia diaphragmatica, intestinal resection, or Nissen fundoplication, and
VAT biopsies were obtained during surgery. Similar exclusion criteria
as mentioned above were applied. In addition, all control subjects had
overall good health without medication and with normal liver function
tests (chronic elevation of transaminase levels indicates liver disease,
i.e., >1.5 times the upper normal value for 3 months). The study
protocol was approved by the Ethics Committee of Ghent University
Hospital and conducted according to the principles of the Declaration
of Helsinki. All participants gave their written informed consent.
Anthropometry and biochemical assays
Anthropometric measurements were performed during a preoperative
examination. Body weight was measured to an accuracy of 0.1 kg in light
indoor clothing without shoes, whereas height was measured using a
wall-mounted stadiometer. Blood samples were collected after overnight
fasting, before surgery, and were centrifuged, fractionated, and stored at
2808C until analysis. Triglyceride and glucose levels were determined
colorimetrically (Roche Diagnostics, Mannheim, Germany), and insulin
levels were measured using electrochemoluminescent immunoassay
(modular immunoassay, Roche Diagnostics). Homeostasis model of the
assessment for insulin resistance (HOMA-IR) was calculated with the
following formula: (fasting glucose [mmol/L] 3 fasting insulin [mU/
mL])/22.5. Aspartate aminotransferase (AST), alanine aminotransferase
(ALT), c-glutamyltransferase (GGT), and C-reactive protein (CRP) were
routinely measured using a conventional automated analyser.
Measurement of adipokine levels
Serum levels of adipokines were measured using commercial enzyme-
linked immunosorbent assay (ELISA) kits, according to manufacturer’s
instructions. Chemerin, MCP-1, and adiponectin were determined with
kits provided by R&D Systems (Minneapolis, MN). The respective
intra- and inter-assay coefficients of variation (CV) were 2.8% and
6.4% for chemerin, 4.9% and 4.6% for MCP-1, and 4.7% and 4.9% for
adiponectin. Omentin serum levels were assessed using the Human
Omentin-1 ELISA kit from BioVendor (Brno, Czech Republic). Intra-
and interassay CV were 3.7% and 4.6%, respectively, for omentin. Cir-
culating levels of SFRP4 were measured using the USCN Life Science
ELISA kit (Hoelzel Diagnostika, Cologne, Germany). Intra- and inter-
assay CV for SFRP4 were<10% and<12%, respectively.
For gene expression analysis, VAT biopsies were collected from the
gastrosplenic or gastrocolic ligaments at the end of surgery from 63
male subjects of the Hepobster cohort (13 controls and 50 subjects
with obesity), immediately frozen, and stored at 2808C until further
use. RNA was isolated from 100 mg of the frozen fat samples with
the TriPure Isolation Reagent kit (Roche Diagnostics) according to
manufacturer’s instructions. Contaminating genomic DNA was
removed with RNase-free DNase incubation (Qiagen, Hilden, Ger-
many), followed by a cleanup step with the RNeasy Mini Kit (Qia-
gen). cDNA synthesis was carried out using the GoScript Reverse
Transcription System (Promega, Mannheim, Germany) according to
manufacturer’s instructions. Expression of MCP-1 and chemerin was
quantified by real-time PCR using the following QuantiTect Primer
Assays: Hs_CCL2_1_SG (MCP-1, CCL2 gene; Cat#QT00212730),
Hs_RARRES2_1_SG (chemerin, RARRES2 gene; Cat#QT00091945)
(Qiagen). Primers to measure omentin (INTL1 gene) and SFRP4
expression were TCAGCTTCCTGCTGTTTCTCATA and GGAGAC
GAAGAACAGGTCCATT for omentin and CACCCATCCCTCGA
ACTCAA and TGTGTGGACACTGGCAAGAAG for SFRP4 (Euro-
gentec, K€oln, Germany). Real-time PCR analysis was carried out on
a StepOnePlus system (Applied Biosystems) with GoTaq qPCR
Master Mix (Promega). Gene expression levels were calculated from
the obtained threshold cycle (Ct) values after normalization for the
expression of stable reference genes, UBE2D2, YWHAZ (Eurogentec),
and RPS18 (QuantiTect Primer Assay, Cat#QT02323251, Qiagen),
using qBase Plus software (version 2.6; Biogazelle, Ghent, Belgium).
Hepatic histopathological analysis
Liver biopsies were obtained from all subjects with obesity at the end
of surgery, each measuring 5 3 5 mm, and were taken from the lateral
edge of the left liver lobe (segment 3) using bipolar forceps. These
were immediately fixated in formalin (buffered 4% paraformaldehyde
solution; Klinipath, Belgium) at room temperature for microscopic
analysis. Formalin fixed liver biopsies were routinely processed and
stained with hematoxylin-eosin and Masson trichrome. An experi-
enced pathologist (MP) established the histological diagnosis of
NAFLD according to the scoring system of Kleiner et al. (16), blinded
to characteristics of participants. At least six complete portal tracts in
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liver specimen were required for adequate histological evaluation. Ste-
atosis was judged as the percentage of hepatocytes containing fat drop-
lets, with a minimum of 5%. NAFLD activity score (NAS) is defined
as the unweighted sum of scores for steatosis intensity (0–3; <5%, 5–
33%, 33–66%, or >66%), lobular inflammation (0–3; no, <2, 2–4, or
>4 inflammatory foci), and hepatocellular ballooning (0–2; no, few, or
many ballooning cells), ranging from 0 to 8 (Figure 1). Scores of 0 to 2
were considered as SS and scores of >5 were considered as NASH.
Intermediate scores of 3 or 4 were considered as borderline NASH
(16). Stage of fibrosis was scored using a 4-point scale.
Statistics
Statistical analysis was performed using IBM SPSS Statistics (ver-
sion 21.0). Data distribution of continuous variables was evaluated
with the Kolmogorov-Smirnov test. Normally distributed variables
were expressed as mean6SD, whereas non-Gaussian distributed
variables were described as median (interquartile range). Adipokines
were compared among the different subject groups, i.e., lean sub-
jects, subjects with obesity but without NAFLD, and subjects with
obesity and NAFLD. Furthermore, among NAFLD patients, adipo-
kines were compared between patients with low, moderate, or high
levels of histopathological severity, i.e., degree of steatosis, hepato-
cyte ballooning, lobular inflammation, and fibrosis. For these com-
parison analyses among the different study groups and histological
parameters, ANOVA and Tukey HSD post hoc test or Kruskal-
Wallis and Mann-Whitney U test were applied. Categorical variables
were analyzed with the v2 test and Fisher’s test. Multivariate analy-
sis was performed to identify independent factors associated with
disease severity in NAFLD patients. Our findings were adjusted for
potential confounders such as age, BMI, and insulin resistance, using
multivariate linear regression analysis (ENTER model).
Results
General characteristics, adipokine serum levels,
and VAT expression in controls and NAFLD
patients
A total of 108 subjects were included in the study cohort (75 men
and 33 women), including 18 normal-weight controls, 9 patients
with obesity but without NAFLD, and 81 patients with obesity and
biopsy-proven NAFLD. NAFLD patients had higher BMI, insulin
levels, HOMA-IR, ALT, GGT, and CRP levels compared with
normal-weight controls, while there were no differences in TG and
AST levels. Twenty-five percent of NAFLD patients had type 2 dia-
betes, whereas none of the controls or patients with obesity but
without NAFLD had diabetes (Table 1).
Serum adiponectin levels were lowest in NAFLD patients compared
with normal-weight controls and obesity patients without NAFLD
(P 5 0.004 and 0.020, respectively), whereas serum MCP-1 levels
were lowest in the obesity without NAFLD group versus controls
and NAFLD patients (P< 0.05). Chemerin serum levels were higher
in NAFLD patients compared with normal-weight controls (P 5
0.020). Circulating omentin and SFRP4 levels were not different
among the groups. With regard to adipokine VAT expression, omen-
tin and SFRP4 were higher (P 5 0.043 and <0.001, respectively),
and chemerin tended to be lower in NAFLD patients compared with
normal-weight controls (P 5 0.053). MCP-1 expression was similar
between control and NAFLD patients (Table 1).
General characteristics and adipokine levels
according to disease severity in NAFLD patients
Potential differences in circulating adipokine levels and VAT expres-
sion were examined in relation to disease severity. From the 81
patients with obesity diagnosed with NAFLD, 32 subjects had SS, 24
subjects borderline NASH, and 25 subjects confirmed NASH. General
characteristics as well as adipokine levels among groups are listed in
Table 2. There were no differences in gender, age, BMI, fasting glu-
cose and insulin, TG, ALT, and CRP levels among the groups.
HOMA-IR, AST, and GGT levels were higher in both borderline and
confirmed NASH patients as compared with those with SS (P5 0.033,
0.023, and 0.002, respectively). There were no clinical or biochemical
differences between borderline NASH and NASH patients.
Serum levels of adiponectin were lower in NASH patients compared
with patients with SS (P 5 0.030). The other serum adipokines
were not different among the three NAFLD groups. Similarly, there
were no differences in VAT expression of adipokines among the
Figure 1 Three different examples of histopathological scoring according to nonalcoholic fatty liver disease (NAFLD) activity score (NAS). (A) Example of a low NAS
(steatosis, grade 2; ballooning, grade 0; lobular inflammation, grade 0; NAS 2) diagnosed as simple steatosis. (B) Example of an intermediate NAS (steatosis, grade
2; ballooning, grade 1; lobular inflammation, grade 1; NAS 4) diagnosed as mild steatohepatitis or borderline nonalcoholic steatohepatitis (NASH). (C) Example of a
high NAS (steatosis, grade 2; ballooning, grade 2; lobular inflammation, grade 1; NAS 5) diagnosed as definite steatohepatitis or NASH (103, hematoxylin and
eosin). [Color figure can be viewed at wileyonlinelibrary.com.]
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groups, except for lower omentin expression in patients with NASH
versus patients with SS (P 5 0.043).
Associations between adipokines and
histopathological grading
We next examined whether adipokine levels and VAT expression
were related to the various histopathological states. As shown in
Figure 2, serum adiponectin levels (r 5 20.308, P 5 0.005; Figure
2A), and chemerin VAT-expression (r 5 20.331, P 5 0.022; Figure
2B) negatively associated with NAS. The other adipokines were
examined similarly and showed no significant relations with NAS.
When considering the individual histopathological parameters, it
was found that serum adiponectin levels and chemerin VAT expres-
sion were lower in patients with moderate or severe steatosis
(>33%) versus patients with mild steatosis (<33%) (P 5 0.001 and
0.007, respectively; Figures 3 and 4). Furthermore, serum adiponec-
tin was lower in patients with higher grades of hepatocyte balloon-
ing, lobular inflammation, and fibrosis (all P< 0.05; Figure 4).
There were no differences in levels of other adipokines, both serum
levels and VAT expression, according to histopathological grading.
Finally, we investigated whether serum adiponectin and chemerin
VAT expression function as independent predictors of NAS in addi-
tion to known confounders such as HOMA-IR and BMI. Among
these patients with NAFLD, BMI was similar in patients with differ-
ent grades of histopathological parameters and did not correlate with
overall NAS. In contrast, HOMA-IR was higher in patients with
higher grades of steatosis, hepatocyte ballooning, and lobular
inflammation (all P< 0.05) and was positively associated with NAS
(r5 0.285, P 5 0.010).
Multivariate linear regression analysis was performed to identify
independent predictors of NAS in NAFLD patients (Table 3).
Whereas the association between HOMA-IR and NAS was inde-
pendent of sex, age, and BMI (model 1), it lost significance after
correcting for chemerin VAT. Chemerin VAT expression remained
negatively associated with NAS, independent of age, BMI, and
HOMA-IR in male NAFLD patients (model 2), whereas adiponectin
TABLE 1 General characteristics of healthy controls, patients with obesity without NAFLD, and patients with obesity and
NAFLD
Parameter
Healthy controls
(N518)
Obesity patients without
NAFLD (N5 9)
NAFLD patients
(N581) P
General characteristics
M/F 18/0 2/7***## 55/26** <0.001
T2D 0 0 20 (25%)* 0.017
Age (years) 446 12 456 9 456 10 0.995
BMI (kg/m2) 24 [22–26] 36 [34–41]***# 41 [38–44]*** <0.001
Glucose (mmol/L) 5.44 [4.63–5.84] 5.11 [4.78–5.86] 5.33 [4.78–6.31] 0.766
Insulin (pmol/L) 25.7 [21.1–40.4] 57.1 [35.8–111.1]** 92.9 [57.5–150.9]*** <0.001
Triglycerides (mg/dL) 156.0 [111.5–204.9] 104.0 [70.5–139.5]*### 185.0 [144.0–241.0] <0.001
HOMA-IR 0.87 [0.60–1.47] 1.79 [1.04–3.89]** 3.21 [1.92–6.10]*** <0.001
AST (IU/L) 22.0 [17.8–33.0] 20.0 [15.5–22.0]# 28.0 [20.0–40.0] 0.023
ALT (IU/L) 11.3 [8.5–29.5] 21.0 [9.0–26.5] 25.0 [14.5–36.5]* 0.036
GGT (U/I) 22.2 [16.0–29.2] 15.0 [10.5–31.0]# 30.0 [19.5–50.5]* 0.009
CRP (mg/L) 1.05 [0.60–2.20] 0.50 [0.15–5.30] 3.00 [1.10–5.35]* 0.046
Serum adipokine levels
Omentin (ng/mL) 398.2 [336.0–490.3] 394.9 [263.4–534.8] 391.6 [307.1–480.7] 0.894
Adiponectin (mg/mL) 6.15 [5.30–10.89] 9.45 [4.10–12.54]# 4.28 [2.94–7.11]** 0.002
Chemerin (ng/mL) 164.7 [112.1–211.0] 177.5 [155.2––235.4] 200.3 [146.6–256.1]* 0.063
MCP-1 (pg/mL) 288.6 [239.5–354.0] 210.1 [192.0–234.8]*## 299.5 [252.4–395.6] 0.010
SFRP4 (pg/mL) 4569.06 2833.8 4255.66 2351.4 4650.86 1805.0 0.709
Adipokine VAT expression, AU
N 15 48
Omentin 1.42 [0.07–13.98] 6.17 [1.98–22.28]* 0.043
Chemerin 1.09 [0.81–1.46] 0.87 [0.62–1.07] 0.053
MCP-1 1.91 [0.20–5.05] 0.58 [0.36–1.59] 0.488
SFRP4 1.01 [0.67–1.23] 2.86 [1.75–4.32]*** <0.001
Data are presented as mean 6 SD or median [interquartile range] and were analyzed using Mann-Whitney U test and v2 test for categorical variables.
*Versus healthy controls; # versus NAFLD patients.
*, #P< 0.05; **, ##P< 0.01; ***, ###P<0.001.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; GGT, gamma-glutamyltransferase; HOMA-IR, homeosta-
sis model of the assessment for insulin resistance; M/F, male-to-female ratio; MCP-1, monocyte chemoattractant protein-1; NAFLD, nonalcoholic fatty liver disease;
SFRP4, secreted frizzled-related protein 4; T2D, type 2 diabetes; VAT, visceral adipose tissue.
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serum levels were no longer associated with NAS after correcting
for sex, age, BMI, and HOMA-IR (model 3). In a final model,
adjusting for adiponectin levels made the relation between chemerin
VAT expression and NAS borderline significant (b520.284, P 5
0.072; model 4).
Discussion
In a group of biopsy-proven NAFLD patients with obesity, we found
lower adiponectin and higher chemerin serum levels as compared
with healthy control subjects. Adiponectin, but not chemerin serum
levels were also associated with disease severity and grade of
steatosis. In contrast to the serum levels, chemerin VAT expression
appeared inversely associated with NAFLD severity, as expression
was significantly lower in patients with higher degrees of steatosis
and overall NAS. This finding persisted after adjustment for age,
BMI, and HOMA-IR. Further, our results suggest that the well-
established link between insulin resistance and NAFLD/NASH
might in part be dependent on VAT expression of chemerin.
NAFLD develops when surplus fat accumulates in the liver, which
might be both resulting from and contributing to insulin resistance.
Indeed, insulin resistance is known to result in an increased hepatic
de novo lipogenesis, together with an increased delivery of lipids to
the liver (17). The prevalence and severity of NAFLD have been
TABLE 2 Clinical and biochemical characteristics of NAFLD patients with obesity plus simple steatosis, borderline NASH, and
NASH
Parameter SS (N5 32)
Borderline
NASH (N5 24) NASH (N5 25) P
Histological grading according to NAS
NAS 1-2 3-4 5-8 <0.001
Steatosis grade (0/1/2/3) 0/26/6/0 0/8/15/1 0/0/5/20 <0.001
Lobular inflammation (0/1/2/3) 27/5/0/0 4/20/0/0 2/16/6/1 <0.001
Hepatocellular ballooning (0/1/2) 31/1/0 2/21/1 0/7/18 <0.001
Fibrosis (0/1/2/3/4) 23/8/1/0/0 6/11/7/0/0 2/12/6/3/1 <0.001
Clinical and biochemical characteristics
M/F 19/13 17/7 19/6 0.384
T2D 4 (12.5%) 10 (42%) 6 (24%) 0.043
Age (years) 436 11 476 11 466 10 0.360
BMI (kg/m2) 42 [39–46] 39 [36–44] 42 [37–43] 0.302
Glucose (mmol/L) 5.25 [4.69–5.67] 5.39 [4.74–7.21] 5.56 [4.97–6.58] 0.376
Insulin (pmol/L) 78.0 [47.9–119.9] 107.6 [76.7–158.8]* 103.7 [57.1–229.2] 0.095
Triglycerides (mg/dL) 178.5 [118.8–215.2] 208.5 [161.8–258.5]* 174.0 [143.5–288.5] 0.129
HOMA-IR 2.41 [1.70–4.08] 4.00 [2.20–7.00]* 3.50 [1.97–8.19]* 0.033
AST (IU/L) 24.5 [17.0–33.5] 25.5 [20.5–40.0] 34.0 [25.0–55.7]** 0.023
ALT (IU/L) 21.2 [15.3–34.0] 29.5 [11.5–35.8] 28.0 [10.0–45.4] 0.607
GGT (U/I) 23.2 [16.0–34.8] 32.0 [20.0–54.5]* 41.5 [28.5–66.5]** 0.002
CRP (mg/L) 2.30 [1.10–5.60] 2.10 [0.70–5.18] 4.10 [1.65–5.48] 0.436
Serum adipokine levels
Omentin (ng/mL) 363.4 [301.8–492.5] 430.3 [313.5–519.7] 353.3 [293.5–437.9] 0.234
Adiponectin (mg/mL) 5.08 [3.56–8.36] 3.99 [2.83–6.39] 4.18 [2.37–4.75]* 0.063
Chemerin (ng/mL) 203.0 [154.0–271.5] 195.9 [147.6–255.7] 202.4 [139.9–232.2] 0.759
MCP-1 (pg/mL) 282.7 [239.9–396.9] 319.9 [274.2–408.5] 300.7 [263.3–381.3] 0.531
SFRP4 (pg/mL) 4725.76 1414.3 4273.46 1754.7 4939.96 2167.4 0.673
Adipokine VAT expression, AU (N5 48)
N 16 16 16
Omentin 16.78 [3.59–36.15] 5.28 [1.59–26.11] 5.87 [1.63–10.86]* 0.166
Chemerin 0.88 [0.65–1.25] 0.97 [0.66–1.07] 0.69 [0.56–0.92] 0.260
MCP-1 0.52 [0.32–2.18] 0.54 [0.32–1.35] 0.66 [0.40–1.43] 0.896
SFRP4 3.78 [1.85–4.59] 2.54 [1.68–3.96] 2.99 [2.07–4.38] 0.484
Data are presented as number of cases, mean 6 SD, and median [interquartile range] and were analyzed using Kruskal-Wallis and Mann-Whitney U test.
*versus SS.
*P< 0.05; **P< 0.01.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; GGT, gamma-glutamyltransferase; HOMA-IR, homeostasis
model of the assessment for insulin resistance; M/F, male-to-female ratio; MCP-1, monocyte chemoattractant protein-1; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD
activity score; NASH, nonalcoholic steatohepatitis; SFRP4, secreted frizzled-related protein 4; SS, simple steatosis; T2D, type 2 diabetes; VAT, visceral adipose tissue.
Obesity Chemerin Expression in Patients with NAFLD Bekaert et al.
2548 Obesity | VOLUME 24 | NUMBER 12 | DECEMBER 2016 www.obesityjournal.org
strongly related to BMI, waist circumference, hyperinsulinemia,
hypertriglyceridemia, impaired glucose tolerance, and type 2 diabe-
tes, which are all metabolic parameters with the common underlying
factor insulin resistance (18,19). Although NAFLD severity did not
associate with BMI in this study, HOMA-IR was associated with
steatosis, hepatocyte ballooning, and lobular inflammation score and
with overall NAS, independent of sex, age, and BMI.
Our study also showed an inverse association between serum adipo-
nectin levels and grade of steatosis, lobular inflammation, hepato-
cyte ballooning, fibrosis, and overall NAS, corroborating previous
findings (20). Adiponectin has an antisteatotic effect on hepatocytes
by increasing fatty acid oxidation and decreasing gluconeogenesis,
fatty acid influx, and de novo lipogenesis (21). Additionally, anti-
inflammatory and antifibrotic effects of hepatic adiponectin have
been reported (22). Recently, a meta-analysis confirmed lower adi-
ponectin levels in NASH/NAFLD compared with controls (23). The
few prospective studies with paired liver biopsies, however, reported
conflicting results and could not always associate adiponectin with
NAFLD progression (24,25). In our multivariate analysis, the
association between NAS and adiponectin was lost when HOMA-IR
was added to the model, suggesting that insulin resistance might
mediate the relation between NAFLD and adiponectin. Since adipo-
nectin is highly associated with insulin resistance, these findings
suggest that low circulating levels of adiponectin may contribute to
insulin resistance, which in turn may influence NAFLD.
Chemerin has been described as a marker of insulin resistance, with
both higher serum levels and adipose tissue expression in patients with
impaired glucose tolerance or type 2 diabetes (26,27). Chemerin has
been reported to interfere with insulin signaling in skeletal muscle
cells and to be implicated in the regulation of inflammation, suggest-
ing a potential involvement in NAFLD (6,7). Indeed, several studies
have reported elevated serum or hepatic expression levels of chemerin
in NAFLD and/or NASH patients and found positive associations with
NAS or hepatic inflammation (28,29). In this study, serum chemerin
levels were higher in patients with NAFLD and obesity compared
with controls; however, they were similar among the three NAFLD
groups and were not related to histopathological severity. In contrast,
chemerin VAT expression had a tendency to be lower in patients with
NAFLD versus controls and was lower in patients with higher grades
of steatosis compared with lower steatosis grades. Chemerin expres-
sion was moderately negatively associated with NAS, independent of
confounding factors. Moreover, the association between HOMA-IR
and NAS lost significance after correcting for chemerin VAT expres-
sion, suggesting that chemerin may at least partly influence the link
between HOMA-IR and NAFLD severity. Recently, Wolfs et al. simi-
larly reported a negative association between chemerin VAT expres-
sion and histopathological parameters of NAFLD patients. In their
study, chemerin expression was negatively associated with steatosis,
lobular, and portal inflammation, independent of obesity, HOMA-IR,
and type 2 diabetes (30). Experimental studies have reported inconsis-
tent results, indicating both pro- and anti-inflammatory properties of
chemerin. It has been described as a chemoattractant of innate immune
cells such as Kupffer cells, which in turn are believed to be key play-
ers in the pathophysiology of NAFLD (31). However, while a mouse
model with diminished chemerin action showed no effects on insulin
resistance and NAFLD compared with wild type (32), the administra-
tion of recombinant chemerin attenuated the inflammatory response in
another model (33). Although the associations were moderate, the
anti-inflammatory effects of chemerin and its negative association with
Figure 2 The inverse relationship between disease severity, presented as the nonalcoholic fatty liver disease (NAFLD) activity
score (NAS) and (A) ln-transformed serum adiponectin (N5 81) as well as (B) visceral adipose tissue expression of chemerin
(N563) in biopsy-proven NAFLD patients.
Figure 3 Chemerin VAT expression was inversely associated with steatosis grade (P
5 0.007; Kruskal-Wallis test). Expression was highest in patients with <33% of ste-
atosis and was lower in patients with moderate (33–66%) to severe (>66%) steato-
sis grade. *P< 0.05; **P< 0.01.
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NAS suggest that this lower VAT expression of chemerin in patients
with obesity may be involved in the pathophysiology of NAFLD.
Importantly, none of the adipokine serum levels were associated with
their respective VAT expression. As the majority of blood flow
(680%) to the liver is delivered via the portal vein, which is closely
connected to VAT, it is likely that systemic serum concentrations of
adipokines do not accurately reflect hepatic delivery of adipokines.
Furthermore, secretion of adipokines is different between subcutaneous
adipose tissue (SAT) and VAT, of which SAT is suggested to contrib-
ute more to systemic levels. Indeed, Alfadda et al. recently highlighted
the differential expression of chemerin between SAT and VAT in sub-
jects with obesity, with higher expression in SAT (34).
Figure 4 Adiponectin serum levels among the histopathological parameters in NAFLD patients. Serum adiponectin was inver-
sely associated with (A) the grade of steatosis, (B) hepatocyte ballooning, (C) lobular inflammation, and (D) fibrosis (P 5
0.001, P 5 0.033, P 5 0.027, and P 5 0.042, respectively; Kruskal-Wallis test among groups), with lower levels in patients
with higher grades. *P< 0.05; **P< 0.01.
TABLE 3 Multivariate linear regression model with NAS as dependent variable in biopsy-proven NAFLD patients
Model 1,
F5 3.028; R250.139
Model 2,
F5 3.209; R25 0.234
Model 3,
F52.742; R25 0.156
Model 4,
F5 2.678; R250.246
Independent
variable b (6SE); P value b (6SE); P value b (6SE); P value b (6SE); P value
Sex 0.244 (60.476); 0.035 Constant 0.209 (60.511); 0.090 Constant
Age 0.205 (60.951); 0.085 0.103 (61.172); 0.505 0.223 (60.951); 0.062 0.114 (61.182); 0.465
HOMA-IR 0.275 (60.265); 0.020 0.244 (60.286); 0.088 0.210 (60.302); 0.116 0.185 (60.323); 0.248
BMI 20.056 (61.484); 0.643 20.211 (62.062); 0.150 20.047 (61.477); 0.693 20.202 (62.077); 0.170
Chemerin VAT
expression
20.317 (60.797); 0.038 20.284 (60.830); 0.072
Serum adiponectin
levels
20.135 (60.379); 0.313 20.128 (60.454); 0.422
Independent variables in the different models were: model 1: sex, age, HOMA-IR and BMI; model 2: sex was constant, age, HOMA-IR, BMI, and chemerin
VAT expression; model 3: sex, age, HOMA-IR, BMI, and serum adiponectin levels; model 4: sex was constant, age, HOMA-IR, BMI, chemerin VAT expression, and serum
adiponectin levels. Data are presented as b coefficients with standard error (SE) of the predicted coefficients (B), and F and R2 values are given per model. Because
visceral adipose tissue (VAT) was only sampled from male patients with NAFLD, sex was constant in model 2 and model 4.
HOMA-IR, homeostasis model of the assessment for insulin resistance; NAS, nonalcoholic fatty liver disease (NAFLD) activity score.
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Other adipokines neither associated with histological parameters nor
with NAFLD severity in our cohort. VAT expression of omentin
and SFRP4 were significantly higher in subjects with obesity versus
controls, without differences in serum levels. This counteracts with
the description of omentin in literature as an anti-inflammatory and
insulin-sensitizing adipokine, of which low serum levels have been
reported in patients with obesity, insulin resistance, and type 2 dia-
betes (35). NAFLD and higher degree of hepatocyte ballooning in
biopsy-proven NAFLD patients have previously been positively
associated with serum omentin levels (36). Higher levels of SFRP4
have been linked to type 2 diabetes and obesity (37) and could be
related to NAFLD because a mouse model with the hepatocyte-
specific knockout of the canonical Wnt pathway was more sensitive
to develop NASH and fibrosis compared with wild type (38). How-
ever, we investigated SFRP4 levels in human NAFLD for the first
time and could not confirm this. Finally, although serum MCP-1
levels were lower in the small group of patients with obesity but
without NAFLD, serum levels nor VAT expression were associated
with histopathological severity. This contrasts with experimental
studies suggesting involvement of MCP-1 in hepatic inflammation
(10,11) and reports of higher MCP-1 levels in NAFLD patients (39).
This study has some limitations. First, the cross-sectional design does
not allow to indicate a causative link or to address the mechanisms
behind the observed associations. These results are thus merely sugges-
tive and need further investigation in larger-scaled prospective studies.
The use of paired biopsies could allow investigating changes of certain
adipokines when NAFLD progresses or regresses over time. Next, the
relatively small sample size among study groups limits the generaliz-
ability of our results and conclusions. Thirdly, patients with obesity,
type 2 diabetes, and NAFLD are closely linked because of the common
causative factor insulin resistance, which makes it difficult to distinguish
metabolic confounding factors. Furthermore, it is known that VAT, and
not SAT, is strongly associated with NAFLD severity (40). In this
cohort, adipose tissue distribution was not assessed, which might poten-
tially explain the lack of association between BMI and NAFLD. Finally,
although liver biopsy is recognized to be the golden standard to diagnose
NAFLD, the chance of sampling error remains inevitable.
In summary, we found that in patients with obesity and NAFLD,
disease severity and the degree of hepatic steatosis inversely associ-
ate with chemerin VAT expression, independent of insulin resist-
ance. These findings suggest a potential role of lowered chemerin
VAT expression in the pathophysiology of hepatic steatosis. More-
over, chemerin VAT expression even appears to modulate the rela-
tion between NAFLD severity and insulin resistance. More knowl-
edge on the determinants of chemerin VAT expression might help
to elucidate the relation between both consequences of obesity.O
Acknowledgments
We thank the staff for their technical assistance and all participants
of the study cohorts.
VC 2016 The Authors. Obesity published by Wiley Periodicals, Inc. on
behalf of The Obesity Society (TOS)
References
1. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature
of the metabolic syndrome. Diabetes 2001;50:1844-1850.
2. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World
J Gastroenterol 2010;16:5286-5296.
3. Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently
described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver
disease: a systematic review. Obes Rev 2016;17:68-80.
4. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the
metabolic syndrome. Ann NY Acad Sci 2010;1212:1-19.
5. Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic
syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab
2009;94:3085-3088.
6. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-
presenting cells by chemerin, a novel processed ligand from human inflammatory
fluids. J Exp Med 2003; 198:977-985.
7. Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived
factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes
2009;58:2731-2740.
8. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific
adipokine in human adipose tissue: possible role in modulating insulin action. Am J
Physiol Endocrinol Metab 2006;290:1253-1261.
9. Greulich S, Chen WJ, Maxhera B, et al. Cardioprotective properties of omentin-1 in
type 2 diabetes: evidence from clinical and in vitro studies. PLoS One 2013;8:e59697.
10. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration
into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest
2006;116:1494-1505.
11. Seki E, de Minicis S, Inokuchi S, et al. CCR2 promotes hepatic fibrosis in mice.
Hepatology 2009;50:185-197.
12. Ehrlund A, Mejhert N, Lorente-Cebrian S, et al. Characterization of the Wnt
inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue. J Clin
Endocrinol Metab 2013;98:503-508.
13. Fuster JJ, Zuriaga MA, Ngo DT, et al. Noncanonical wnt signaling promotes
obesity-induced adipose tissue inflammation and metabolic dysfunction independent
of adipose tissue expansion. Diabetes 2015;64:1235-1248.
14. Zeng G, Awan F, Otruba W, et al. Wnt’er in liver: expression of Wnt and frizzled
genes in mouse. Hepatology 2007;45:195-204.
15. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M.
Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the
pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007;47:571-579.
16. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological
scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
17. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ.
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with
nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351.
18. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Non-alcoholic
fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 2004;
36:165-173.
19. Musso G, Cassader M, De Michieli F, Rosina F, Orlandi F, Gambino R.
Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and
dysfunctional response to fat ingestion predict liver injury and altered glucose and
lipoprotein metabolism. Hepatology 2012;56:933-942.
20. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver
disease. Metabolism 2016;65:1062-1079.
21. Heiker JT, Kosel D, Beck-Sickinger AG. Molecular mechanisms of signal transduction
via adiponectin and adiponectin receptors. Biol Chem 2010;391:1005-1018.
22. Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis. Trends Endocrinol
Metab 2015;26:153-161.
23. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total
adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-
analysis. Metabolism 2011;60:313-326.
24. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty
liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010;59:
969-974.
25. Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of
NAFLD in the general population during a seven-year prospective follow-up.
J Hepatol 2012;56:1145-1151.
26. Ouwens DM, Bekaert M, Lapauw B, et al. Chemerin as biomarker for insulin
sensitivity in males without typical characteristics of metabolic syndrome. Arch
Physiol Biochem 2012;118:135-138.
27. Chakaroun R, Raschpichler M, Kloting N, et al. Effects of weight loss and exercise
on chemerin serum concentrations and adipose tissue expression in human obesity.
Metabolism 2012;61:706-714.
28. Sell H, Divoux A, Poitou C, et al. Chemerin correlates with markers for fatty liver
in morbidly obese patients and strongly decreases after weight loss induced by
bariatric surgery. J Clin Endocrinol Metab 2010;95:2892-2896.
29. Docke S, Lock JF, Birkenfeld AL, et al. Elevated hepatic chemerin mRNA
expression in human non-alcoholic fatty liver disease. Eur J Endocrinol 2013;169:
547-557.
Original Article Obesity
OBESITY BIOLOGY AND INTEGRATED PHYSIOLOGY
www.obesityjournal.org Obesity | VOLUME 24 | NUMBER 12 | DECEMBER 2016 2551
30. Wolfs MG, Gruben N, Rensen SS, et al. Determining the association between
adipokine expression in multiple tissues and phenotypic features of non-alcoholic
fatty liver disease in obesity. Nutr Diabetes 2015;5:e146.
31. Wittamer V, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D.
Neutrophil-mediated maturation of chemerin: a link between innate and adaptive
immunity. J Immunol 2005;175:487-493.
32. Gruben N, Aparicio Vergara M, Kloosterhuis NJ, et al. Chemokine-like receptor 1
deficiency does not affect the development of insulin resistance and nonalcoholic
fatty liver disease in mice. PLoS One 2014;9:e96345.
33. Luangsay S, Wittamer V, Bondue B, et al. Mouse ChemR23 is expressed in
dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity
of chemerin in a lung disease model. J Immunol 2009;183:6489-6499.
34. Alfadda AA, Sallam RM, Chishti MA, et al. Differential patterns of serum
concentration and adipose tissue expression of chemerin in obesity: adipose depot
specificity and gender dimorphism. Mol Cells 2012;33:591-596.
35. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene
expression are decreased in obesity. Diabetes 2007;56:1655-1661.
36. Yilmaz Y, Yonal O, Kurt R, et al. Serum levels of omentin, chemerin and adipsin in
patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol
2011;46:91-97.
37. Mahdi T, Hanzelmann S, Salehi A, et al. Secreted frizzled-related protein 4 reduces
insulin secretion and is overexpressed in type 2 diabetes. Cell Metab 2012;16:625-633.
38. Behari J, Yeh TH, Krauland L, et al. Liver-specific beta-catenin knockout mice
exhibit defective bile acid and cholesterol homeostasis and increased susceptibility
to diet-induced steatohepatitis. Am J Pathol 2010;176:744-753.
39. Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in
nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.
J Hepatol 2006;44:1167-1174.
40. Kim D, Chung GE, Kwak MS, et al. Body fat distribution and risk of incident and
regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016;14:132-138.
Obesity Chemerin Expression in Patients with NAFLD Bekaert et al.
2552 Obesity | VOLUME 24 | NUMBER 12 | DECEMBER 2016 www.obesityjournal.org
